Skip to main content
MMedVellum
MCQsExamsAtlas
DashboardPricing
MMedVellum

The exam atlas that feels like a flagship product — evidence-graded topics and exam tools for MBBS and fellowship preparation. Built to scale to fifty specialties. Educational content only — not medical advice.

llms.txt·psychiatry LLM catalog · sitemap

Atlas

  • Specialty atlas
  • MBBS / Core medicine
  • Dermatology
  • ICU Fellowship (CICM)
  • Anaesthesia
  • Emergency Medicine
  • Psychiatry Fellowship

Study & account

  • MCQ practice
  • Practice alias
  • Exam tools
  • Dashboard
  • Pricing
  • Sign in

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

Clinical Atlas Prestige · Evidence-first

Psych VivasAddiction psychiatry — public health and systems

Psych Vivas · Addiction psychiatry — public health and systems

Harm reduction — structured clinical viva

Fellowship viva integrating post-overdose care, THN, NSP, OAT re-engagement, HCV, and anti-stigma communication.

clinical
On this page & tools

Target exams

FRANZCPMRCPsychABPNMD-DNB

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
You are the psychiatry registrar on call. A 45-year-old woman is brought to ED after her partner used intranasal naloxone when she was found unresponsive with pinpoint pupils and respiratory rate 4/min. She is now irritable and in moderate opioid withdrawal. She injects heroin and sometimes methamphetamine, uses the needle exchange irregularly, has hepatitis C antibody positive status without RNA follow-up, and was removed from a methadone programme 6 weeks ago after missing three doses and then using. The ED consultant asks whether giving her clean needles and another naloxone kit is 'enabling' and whether you should insist on detox only. Discuss your formulation, acute plan, public-health rationale, and how you would speak with staff about stigma.

Interpretation

Reveal interpretation

This is a post-overdose systems and ethics viva, not a simple detox request. She has just survived a life-threatening opioid overdose; partner-administered naloxone was appropriate first aid. She is now in withdrawal — a high-craving, high-relapse state — and has lost OAT continuity, a period when mortality risk rises (Sordo). Framing sterile equipment or naloxone as “enabling” misreads the evidence: take-home naloxone programmes reduce overdose mortality, and NSP associates with reduced HIV transmission.[1][2][3]

Acute priorities. Medical observation for re-sedation (especially if long-acting opioids or fentanyl possible); manage withdrawal supportively; offer same-episode restart of OAT (buprenorphine if adequate withdrawal and local protocol allow; or methadone re-induction low and slow — not automatic return to a prior high dose after gap); supply take-home naloxone and train her and her partner; facilitate NSP access; arrange HCV RNA and antiviral pathway; assess stimulant co-use, suicide risk, housing, children/safeguarding.[1][2][5]

Detox only. A short detox without maintenance and without overdose prevention is not the safer moral high ground when tolerance is falling — counsel mortality data and shared decision-making.[2]

Staff stigma conversation. Use Volkow’s framing: stigma delays care and increases the toll of addiction. Person-first language; reject “dirty urine” culture; explain that retaining people in care is the clinical goal. Hawk: accountability without termination.[4][5]

Key points

Post-overdose bundle

Observe, THN, MOUD offer, NSP, BBV linkage — not lecture-and-discharge.

Retention over optics

Mortality rises after leaving OAT; restart carefully after missed doses.

Enabling is the wrong word

Naloxone and sterile equipment are evidence-based harm reduction, not moral failure.
[1] [2] [3] [4]

References

  1. [1]McDonald R, Strang J Are take-home naloxone programmes effective? Addiction, 2016.PMID 27028542
  2. [2]Sordo L, et al. Mortality risk during and after opioid substitution treatment BMJ, 2017.PMID 28446428
  3. [3]Aspinall EJ, et al. Needle and syringe programmes and HIV transmission Int J Epidemiol, 2014.PMID 24374889
  4. [4]Volkow ND Stigma and the Toll of Addiction N Engl J Med, 2020.PMID 32242351
  5. [5]Hawk M, et al. Harm reduction principles for healthcare settings Harm Reduct J, 2017.PMID 29065896